News

CMN Weekly (18 February 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Feb. 18, 2022

Top Picks

Research

Industry

  • Synthego has raised $200 million of growth capital in a Series E financing. The financing will be used to further develop its Halo and Eclipse platforms and its next-generation technology CRISPROff. The company also announced that it recently appointed Avi Raval as chief financial officer. Mr Raval comes from a position as a managing director and founding member of the health care group at Perella Weinberg Partners.
  • Intellia and ONK Therapeutics have announced a licensing and collaboration agreement to advance allogeneic CRISPR-edited NK cell therapies for the treatment of patients with cancer. In the agreement, ONK will have non-exclusive rights to Intellia's ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell therapies. Intellia will in return receive global co-development and co-commercialization options for up to two CRISPR-edited NK cell therapies with lead commercialization rights in the U.S.
  • CRISPR Therapeutics has reported a net income of $377.7 million for the full year 2021 and a cash position of $2,379.1 million. In a business update, the company reports that more than 70 patients have now been dosed with CTX001 for the treatment of beta-thalassemia and sickle-cell disease, that the first patient has been dosed with VCTX210 for the treatment of type 1 diabetes, and that other clinical trials are progressing.
  • Business Insider has published a narrative by Andrew Dunn about Shakked Halperin, CEO of Rewrite Therapeutics that was recently sold to Intellia Therapeutics for $45 million cash and an additional $155 million in milestones. Halperin founded the company in 2020 and raised just $2 million before selling it for potentially 100 times as much.

Detection

Reviews

Meetings and webinars

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (18 February 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
Solid tumors, (NCT05361174)
Sponsors:
Iovance Biotherapeutics, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT05329649)
Sponsors:
Vertex Pharmaceuticals Incorporated
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine